Zevra Therapeutics Board And Management Urge Stockholders to Vote "FOR" Zevra's Director Nominees on WHITE Proxy Card

Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team

Zevra Continues Growth Trajectory into a Global Commercial Rare Disease Company with Consistent Execution, New Product Launches, and Significant Financial Flexibility to Execute Strategic Plan

Urges Stockholders to Defend Board Independence from Majority Influence by Individual 2.8% Stockholder, Mangless, Who Had Three Nominees Elected to the Board in 2023

Mangless Has Not Detailed any Strategies, Plans, or New Ideas to Improve Zevra's Business and Appears Solely Focused on Replacing Two Highly Qualified Directors

Board and Management Urge Stockholders to Vote "FOR" Zevra's Highly-Qualified and Experienced Director Nominees on the WHITE Proxy Card

 

CELEBRATION, Fla., April 21, 2025 (GLOBE NEWSWIRE) --  Zevra Therapeutics, Inc. (NASDAQ:ZVRA) ("Zevra", or "the Company"), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's 2025 Annual Meeting of Stockholders ("Annual Meeting"), which is scheduled to take place on May 29, 2025. Stockholders of record as of April 4, 2025 will be entitled to vote at the Annual Meeting.

Zevra's Board of Directors strongly recommends that stockholders vote "FOR" the Company's two highly-qualified directors up for re-election on the WHITE proxy card – Wendy L. Dixon, Ph.D and Tamara A. Favorito, both of whom bring extensive public company board experience and life sciences management expertise to the Zevra Board. Both of these independent directors have contributed valuable perspectives that have helped accelerate the Company's progress and execution of its strategic goals.

In conjunction with the definitive proxy filing, Zevra is mailing a letter to stockholders detailing the decisive action the Company has taken over the past two years to transform Zevra into a stronger, growth-oriented commercial organization, which is poised to continue to drive significant stockholder value. The letter also addresses the attempt by an individual stockholder, Daniel J. Mangless, to replace two highly qualified directors with his nominees who could disrupt the clear progress underway and jeopardize Zevra's ability to deliver long-term value for stockholders.